DIAgnosing GDM usiNg Oral Sugar InStead

Diabetes, Gestational Clinical Trial

— DIAGNOSIS  

Official title:

Randomized Crossover Study Comparing the Standard Glucose Beverage and Dex4® Tablets for 2 Hour Oral Glucose Tolerance Testing in Pregnant Women With a Positive Screen on the 50g Glucose Tolerance Challenge for Gestational Diabetes

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05115188
• Other study ID #: REB 418-2018
• Status: Recruiting
• Phase: Phase 2
• Start date: October 1, 2022
• Est. completion date: December 2024

Study information

• Verified date: August 2023
• Source: Sunnybrook Health Sciences Centre
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to compare the positive and negative effects of Dex4® tablets, as an alternative form of fast acting carbohydrate, compared to the current standard diagnostic test, glucose beverage. The investigators hypothesis that because of their availability in solid, chewable form, variety of flavours and lack of carbonation, Dex4® tablets may result in fewer side effects than glucose beverage and provide an equivalent carbohydrate challenge for diagnosis of gestational diabetes.

Description:

The project is a prospective randomized crossover study. Women who fall into the screen positive group of the 50g GCT (1 hour serum glucose of 7.8-11.0 mmol/L) will be offered participation in the study. Forty-two participants will be recruited and will be randomly assigned using a pre-populated allocation table to take either the standard OGTT test (75g of glucose beverage) first or the alternative OGTT test (21 Dex4® tablets) first. The first test will be referred to as OGTT-1 and the second test will be referred to as OGTT-2. After completing OGTT-1 at the first test appointment, a questionnaire about side effects from the first test will be completed. After completing OGTT-2 at their second test appointment, a questionnaire about side effects from the second test and test preference will be completed. Each woman will complete both tests within one week and each subject will serve as their own control. Results will be kept blinded in the case report forms until both OGTT tests are done. Serum glucose will be measured using the same internationally standardised glucose-oxidase method (RocheDiagnosis) in the Sunnybrook Biochemistry lab. After serum glucose measurement, all results will be sent to the research team but only the standard of care glucose beverage test data will appear in electronic (or classical) medical records and be used for GDM diagnosis.

The participant population consists of 28 pregnant women between 24-32 weeks' gestation who have screened positive for gestational diabetes on the 50g glucose challenge test. The main drawback to participation is that women will have to undergo two fasting, 1 hour and 2 hour glucose tests within one week. Risks involved with participating in the study include: possibility of pain, bruising, swelling or infection related to drawing blood, allergic reaction symptoms such as itching, facial swelling and anaphylaxis upon consumption if the participant has an allergy to corn based products such as dextrose. These risks will be minimized by screening patients for dextrose allergy before having them sign the informed consent form.

The benefit may not be directly to the patient as they will still need to complete the standard 75g glucose beverage test but they will be contributing to new knowledge on alternatives to the standard test that may benefit other pregnant women, including themselves, in the future.

The ultimate goal of this project is to improve women's health by 1) allowing more women to be screened for GDM and 2) providing an equivalent glucose beverage alternative with fewer side effects, making the screening process more comfortable for patients who cannot tolerate glucose beverage. Improving the tolerability of the test is important because there is growing evidence that GDM significantly increases the risk of short and long term adverse consequences for both the fetus and the mother (10,11). Accurate diagnosis may allow women to implement preventative measures such as a healthy lifestyle, which has shown to be effective in preventing T2DM in women with previous GDM (19,20). There have been recent quality control issues with the commercially available glucose beverage product (16), so this alternative test could become the standard test if the dose calibration is found to be more reliable.

Primary objective 1 (PO-1): to determine if Dex4® tablets is equivalent to glucose beverage for use in the 2-hr 75g OGTT in pregnant women between 24-32 weeks' gestation who have screened positive for GDM.

Secondary objective (SO-1): to determine if women have fewer side effects and prefer the standard (glucose beverage) OGTT test or the alternative (Dex4® tablets) OGTT test

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 42
• Est. completion date: December 2024
• Est. primary completion date: December 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: N/A and older

Eligibility

Eligibility criteria must be met by 32 weeks' gestation to allow enrollment in the study.

Inclusion Criteria:

• Positive 50g GCT result between 7.8-11.0 mmol/L

• Female

• Singleton pregnancy

• Informed consent obtained and signed

Exclusion Criteria:

• Use of steroids, terbutaline, or metformin within the last 4 weeks

• Previous diagnosis of diabetes type 1 or 2 outside of pregnancy or diagnosis with any form of diabetes prior to 20 weeks of pregnancy

• Allergy to any ingredients (including the non-medicinal ingredients) in Dex4® tablets or Glucodex solution

Related Conditions & MeSH terms

• Diabetes, Gestational

Intervention

Dietary Supplement:
• Dex4/ dextrose
Participants will be asked to ingest 21 Dex4® tablets and no more than 300ml of water within 5 minutes. Blood draws will be performed at fasting (before ingesting the dextrose monohydrate tablets), as well as 1 hour after (+/- 15 minutes) and 2 hours (+/- 15 minutes) after ingesting the dextrose monohydrate tablets.
• Glucose beverage
For the 2 hour oral glucose tolerance test (OGTT), women fast for 8 hours and then consume 75g of glucose beverage, and serum glucose levels are taken at fasting, 1 and 2 hours after drinking the glucose beverage. The 75g OGTT is the gold standard and is performed for GDM diagnosis.

Locations

Country	Name	City	State
Canada	Sunnybrook Health Sciences Centre	Toronto	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
Sunnybrook Health Sciences Centre

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Glucose values in the oral glucose tolerance test	To determine if Dex4® tablets is equivalent to glucose beverage for use in the 75g OGTT in pregnant women between 24-30 weeks gestation who have screened positive for GDM. Fasting, 1hr, and 2 hr levels from the Dex4 OGTT are within 20% of the levels from the glucose beverage OGTT.	Within 7 days
Secondary	Adverse effect - nausea (qualitative measurement)	Patient has self-reported symptoms of nausea after OGTT. Collected via questionnaire.	Within 2 hours after glucose ingestion
Secondary	Adverse effect - vomiting (qualitative measurement)	Patient has self-reported symptoms of vomiting after OGTT. Collected via questionnaire.	Within 2 hours after glucose ingestion
Secondary	Adverse effect - dizziness (qualitative measurement)	Patient has self-reported symptoms of dizziness after OGTT. Collected via questionnaire.	Within 2 hours after glucose ingestion
Secondary	Adverse effect - headache (qualitative measurement)	Patient has self-reported symptoms of headache after OGTT. Collected via questionnaire.	Within 2 hours after glucose ingestion
Secondary	Adverse effect - sweating (qualitative measurement)	Patient has self-reported symptoms of sweating after OGTT. Collected via questionnaire.	Within 2 hours after glucose ingestion
Secondary	Adverse effect - other (qualitative measurement)	Patient has self-reported other symptoms after OGTT. Collected via questionnaire.	Within 2 hours after glucose ingestion
Secondary	Participant preference - qualitative measurement	Patient reports whether she preferred Dex4 OGTT, glucose beverage OGTT, or no preference. Collected via questionnaire.	Immediately after completion of both study arms